Europe-Wide Launch of Interventional Ultrasonic Endoscope
FUJIFILM's EG-740UT now available throughout Europe
Ultrasonic Endoscope EG-740UT
RATINGEN, Germany, March 28, 2025 (GLOBE NEWSWIRE) -- The FUJIFILM Healthcare Europe Team are delighted to announce the Europe-wide release of the EG-740UT interventional Ultrasonic Endoscope with enhanced visibility, manoeuvrability and single crystal image quality, designed for therapeutic use.
'I'm excited about the European-wide launch of our ultrasonic endoscope and the opportunity to support clinicians with greater comfort and confidence during their work, both endoscopically and through ultrasound imaging. With the EG-740UT, we are marking significant advancements in interventional EUS and EURCP with an all-encompassing EUS solution that supports the diagnosis to treatment journey. Over 90 years of imaging heritage has given us an opportunity to combine expertise from endoscopy, x-ray and ultrasound to become a partner for all imaging needs within Endoscopic Ultrasound.'SINGLE CRYSTAL TECHNOLOGYAlthough is widely utilised in general ultrasound devices, FUJIFILM is one of the first innovators to develop the that is incorporated into the EG-740UT Ultrasonic Endoscope.
This specialist technology has been developed to provide highly sensitive and accurate echo detection, combined with lower-noise imaging that helps reduce the need for additional processing. When paired with our advanced imaging modalities such as Detective Flow Imaging (DFI), Contrast Harmonic Imaging (CHI) and ShearWave Measurement (SWM) provided by the ARIETTA® ultrasound platforms, this endoscope is designed to deliver exceptional image quality during diagnostic procedures with higher resolution and increased depth compared to previous generations.
DESIGNED FOR THERAPEUTIC USEWith a 4.0 mm working channel and slim insertion portion that includes a short bending radius and high deflection, the EG-740UT ultrasonic endoscope is designed for therapeutic use. Especially crafted for comfort and confidence during procedures, this interventional endoscope has been developed to improve visibility in endoscopic and ultrasound images by between the working channel outlet, ultrasound scanning area and endoscopic view.
VISIT FUJIFILM IN BARCELONA FOR ESGE DAYS 2025April 3-5, Booth #04 / EndoRunner Square #22
Join the FUJIFILM Healthcare Europe team in Barcelona for ESGE Days 2025 to experience this new ultrasound endoscope and other new endoscopy solutions!
Participate in our Industry Symposium on Friday 4th April to learn more about the science behind our innovations and hear from a world-class international faculty about their experiences.
ADD TO YOUR CALENDAR: Please visit ESGE Days | European Society of Gastrointestinal Endoscopy to see the full list events and add events to your calendar.
LEARN MOREStay in the loop with newsletters, events and product release notifications from the FUJIFILM Healthcare Europe Team: https://www.healthcare-eu.fujifilm.com/welcome-future/
CONTACT USWould you like to learn more or perhaps you have a question for our team?
Get in touch below.
Stefan Bachmeier, Marketing Manager Europe Endoscopy Systems, FUJIFILM Healthcare Europe GmbH
endoscopy_eu@fujifilm.com
As a global innovator for over 90 years in healthcare and imaging, Fujifilm's innovative endoscopy solutions are designed to improve patient accessibility to healthcare services, with early diagnosis and medical treatments that deliver a continued positive impact on our society. With our knowledge, passion and inspiration, we empower endoscopy professionals to make the biggest difference in their daily work .
Together, we are enriching lives and giving the world more smiles!A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b722c5ae-1804-4daf-bf62-7338b4438873Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
22 minutes ago
- Business Upturn
PFM Crypto Allocates $1M Reward Pool for New AI-Driven 1-Day Mining Contracts
By GlobeNewswire Published on June 29, 2025, 13:00 IST LOS ANGELES, June 29, 2025 (GLOBE NEWSWIRE) — PFM Crypto, the world's leading crypto asset management platform, has officially launched its innovative '1-Day Contract,' providing new users with a flexible, low-risk way to experience the platform's capabilities. This product debut coincides with a major promotional campaign featuring over $1 million in giveaways, including a $10 bonus for every new registrant. Click here to explore more about PFMCrypto. What is PFM Crypto? Why Now? PFM Crypto has built an intelligent, accessible, and sustainable crypto asset management ecosystem. At its core lies the proprietary PFM-AI system, which dynamically reallocates assets across high-potential cryptocurrencies based on real-time market data to optimize returns. With the '1-Day Contract' launch, PFM Crypto [ transitions from a high-performance niche platform to an open model welcoming retail traders and everyday investors worldwide. The platform currently serves over 9.2 million users across 192 countries, with recent performance metrics including:5-Day Contract Strategy: +6.15% returns15-Day Contract Strategy: +20.7% returns30-Day Contract Strategy: +55.6% returns These figures represent actual user results – not projections – demonstrating PFM Crypto's AI-driven yield optimization and results-focused operational model. '1-Day Contract' Launch Details The new product becomes available today, across PFM Crypto's web and mobile platforms. Priced at just $10 with $0.60 daily returns, it offers an accessible entry point to PFM Crypto's growing ecosystem. $1M+ Community Rewards Campaign To celebrate the launch, PFM Crypto has initiated a board-approved rewards program exceeding $1 million. The campaign provides truly barrier-free trial opportunities – all new registrants receive a $10 bonus credited to their account dashboard. Click here to become a new user of PFMCrypto. Highlights of the Limited-Time Campaign:– Intensive 24-Hour Mining Window: Designed for accelerated gains, users can mine XRP in a time-optimized format.– $1M in Mining Rewards: With structured reward tiers of $10/ $35 / $1,800 / $4,800, PFMCrypto is incentivizing both new and existing miners to participate.– Enhanced Daily Yields: Participants will enjoy higher-than-usual mining returns for the duration of the promotion. This bold marketing initiative aims to attract new users, encourage sharing, and demonstrate PFM Crypto's core product value. Click here to view the limited time mining campaign. Significance for Crypto Investors PFM Crypto combines AI innovation, fintech advancement, and practical cryptocurrency functionality – three powerful elements resonating with global crypto investors. It delivers returns without requiring deep technical or trading expertise. Why PFMCrypto Is the Go-To Choice for XRP Mining Beginners and Veterans Alike: – No Equipment Required: Access institutional-grade mining capacity instantly. – Zero Maintenance Fees: PFMCrypto handles electricity, cooling, and hardware upkeep—users simply activate their plans. – $10 Welcome Bonus: Every new user receives a sign-up reward and daily login incentives. – Daily Payouts + Capital Security: Users earn daily income, with the principal returned upon contract maturity. By focusing on measurable performance rather than hype, PFM Crypto has established itself as an enduring value proposition in the crypto investment ecosystem. About PFM CryptoOperated by FCA-regulated Precision Financial Management Ltd (Company No. 11719896), PFM Crypto represents a new category of digital asset platforms – data-driven, performance-focused, and globally trusted. Since its 2018 founding, the Leyland-based company has grown into one of the year's most compelling crypto investment opportunities for return-oriented (rather than speculative) investors. For complete details and participation: Media Contact: Amelia ElspethPFMcrypto [email protected] A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Washington Post
an hour ago
- Washington Post
Can France, land of smoking and joie de vivre, end its cigarette habit?
VAUCLUSE, France — In a country where the cigarette holds an iconic status on par with the croissant or glass of red wine, a ban from Sunday on smoking in all parks, beaches and bus stops has ignited a fiery debate, pitting laissez-faire libertines against those worried by the serious health implications of France's stubbornly high smoking rates.
Yahoo
an hour ago
- Yahoo
Johnson & Johnson's (JNJ) IMAAVY Demonstrates Superior gMG Control
Johnson & Johnson (NYSE:JNJ) is one of the 12 stocks that will make you rich in 10 years. On June 23, J&J announced new data from an indirect treatment comparison (ITC) study. The data show that the company's drug, IMAAVY (nipocalimab-aahu), demonstrated consistent and sustained disease control in patients with generalized myasthenia gravis (gMG) compared to other approved FcRn blockers. The findings were presented at the European Academy of Neurology (EAN) 2025 Congress in Helsinki, Finland. Gil C/ According to the findings, IMAAVY showed a comparable onset of symptom relief at Week 1. The drug demonstrated consistent and sustained disease control over multiple timepoints up to 24 weeks. More importantly, IMAAVY showed greater or statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores compared to the published Phase 3 data of other FcRn blockers. The drug received FDA approval on April 30, 2025, for adults and pediatric patients aged 12 and older with anti-AChR or anti-MuSK antibody-positive gMG. This makes IMAAVY the first and only FcRn blocker approved for both antibody types, covering ≥90% of antibody-positive gMG patients. Johnson & Johnson (NYSE:JNJ) is a global healthcare company. It develops, manufactures, and sells pharmaceuticals and medical devices through two main segments: Innovative Medicine and MedTech. Its key pharmaceutical products include Darzalex, Stelara, Tremfya, and Carvykti, while its MedTech offerings span surgical technologies, orthopedics, and vision care. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
